Metropolis Healthcare Ltd. · NSE:METROPOLIS
Metropolis Healthcare — Q1 FY2024 Earnings Presentation
28 slides from Metropolis Healthcare's earnings presentation, Aug 2, 2023
Slide 1: Exchange filing cover letter: intimation of investor presentation
Ref: MHL/Sec&Legal/2023-24/40 Date: August 02, 2023 To, To, Head, Listing Compliance Department Head, Listing Compliance Department, BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No. C/1. G Block, Dalal Street, Mumbai – 400 001. Bandra – Kurla
Slide 2: Reaching Out Responsibly - Investor Presentation August 2023
Reaching Out RESPONSIBLY Investor Presentation – August 2023
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Metropolis Healthcare Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Q1FY24 Performance
QiFY24 Performance...
Slide 5: Q1FY24 Performance Snapshot
Q1FY24 Performance Snapshot Total Revenue Core Business* Revenue Rs. 277 Crores Rs. 271 Crores -1% YoY 12% YoY Core Business* Volume Core Business* RPT 5.4 Mn Rs. 501 9% YoY 3% YoY EBITDA Margin Reported EBITDA Margin (Before CSR & ESOP) 24.2% 23.3% Q1FY24 Key Highlights 4 *Core business excludes re
Slide 6: Q1FY24 Key Highlights
Q1FY24 Key Highlights Core Business* Revenue grew at 12% Core business revenues grew at 12% with 9% volume growth and 3% RPT growth 01 B2C revenues grew by 13% B2C revenues grew by 13% for Q1FY24 Y-o-Y with Volume growth of 9% & RPT 02 growth of 4%. B2C revenue in Mumbai by 15% B2B segment holding g
Slide 7: Core Business Revenue continues to grow by double digit
1a. Core Business Revenue continue to grow by double digit.. Core Business PPP Contracts Covid PCR & Covid Allied Total Revenues (incl. Hi-Tech) +12% -1% -71% 271 20 19 280 277 241 One of the large PPP Contract ended on 8th February 2023 5 1 Q1FY23 Q1FY24 Q1FY23 Q1FY24 Q1FY23 Q1FY24 Q1FY23 Q1FY24 ✓
Slide 8: 9% volume growth and 3% RPT growth
1b. …with 9% volume growth & 3% RPT growth Core Business No. of Patient Visits (In Mn.) Core Business Revenue Per Patient (In Rs.) +8.9% +3.2% 2.5 2.7 975 1,006 Q1FY23 Q1FY24 Q1FY23 Q1FY24 Core Business No. of Tests (In Mn.) Core Business Revenue Per Test (In Rs.) +8.8% +3.2% 5.0 5.4 486 501 Q1FY23
Slide 9: B2C revenue grew by 13%
2. B2C revenue grew by 13% & B2C revenue in Mumbai grew by 15% Revenue Mix Across Segments B2C Revenue (Rs. Crs) +13% 10% 8% B2C revenues grew by 13% Y-o-Y with Volume 138 growth of 9% & RPT growth of 4% 123 Q1FY23 50% Q1FY24 52% 40% 40% B2C revenue in Mumbai grew by 15% Q1FY23 Q1FY24 B2C B2B Others
Slide 10: B2B segment Specialized testing growing at 13%
3. B2B segment Specialized testing growing @ 13% Revenue Mix Across Segments B2B Revenue Mix (Rs. Crs) +9% 10% 8% B2B contributes 40% of revenues for Q1FY24 108 99 Q1FY23 50% Q1FY24 52% B2B revenues grew by 9% for Q1FY24 Y-o-Y 40% 40% with Volume growth of 6% & RPT growth of 3% Q1FY23 Q1FY24 B2C B2B
Slide 11: Premium Wellness revenue grew 27% with 38% volume growth
4. Premium Wellness revenue grew @ 27% with 38% volume growth Population for Diagnostic Industry Total Premium Wellness Revenue (excl. Covid & Allied) 45% 6% 106 94% 73 27% 40 32 Wellness Population Illness Population Q1FY23 Q1FY24 FY22 FY23 ✓ Revenue from Premium Wellness has grown by 27% on Y-o-Y
Slide 12: Expanding Network
5a. Expanding Network… Laboratory Network - MHL Service Network - MHL Hitech Network Total Network Rationalization ARC Period Lab network Service network +118 Centers Total 180 Total 3,693 + 6 labs Third Party PSCs Owned PSCs 3,612 3,730 63 Laboratory Network 19 155 161 3,064 754 761 19 Labs 141 2,7
Slide 13: Scaling productivity of new labs
5b. …while scaling productivity…. Revenue Labs started in FY22 Revenue for Labs started in FY22 (Base to 100) (Base to 100) +204% +19% 304 119 Total Revenue from labs started in last 24 months 100 stood at Rs. 46 crs in FY23 For Q1FY24 the revenue for labs started in last 27 100 months stood at Rs.
Slide 14: Improving profitability: lab maturity cycle
5c. …and improving profitability Network Expansion Lab Maturity Cycle 42 labs EBIDTA Margin Period 155 161 Profile 141 119 124 125 0-12 months -5% FY19 FY20 FY21 FY22 FY23 Q1FY24 12-18 months +5% Labs Added NA 5 1 16 14 6 18-24 months +15% EBIDTA NA 0.3% 0.3% 1.0% 1.2% 1.1% Dilution* Company Acceler
Slide 15: EBITDA margins before Network Expansion at 25.3%
6. EBIDTA margins before Network Expansion for Q1FY24 stood @ 25.3%* Dilution of EBIDTA margins ~110 bps is on account of Network expansion undertaken after April 2022 Higher Throughput from Incremental Volumes from High operating leverage play & Existing Network Network Expansion increasing margin
Slide 16: International business
International business Our International Presence B2B Locations Kenya Zambia Ghana Tanzania Uganda via Franchisee Year of Inception Year of Inception Year of Inception Year of Inception Year of Inception 2013 2015 2014 2018 2022 Samples brought at GRL from 9 6 4 3 1 10+ Countries Labs/Diagnostics La
Slide 17: Specialized and Premium Wellness revenue contribution continues to grow
Specialized and Premium Wellness revenue contribution continues to grow Strong Brand Equity across markets & Doctors Trust and Reliance on Metropolis helps us grow our Specialized & Premium Wellness segment faster than the Industry Q1FY23 Q1FY24 Specialized (Rs. Crs) Premium Wellness (Rs. Crs) Core
Slide 18: Diversified Revenue contribution across Geographies
Diversified Revenue contribution across Geographies Continue to focus on strengthening the Brand in Focus cities through increase in B2C share while improving the share of Seeding and Other cities through a healthy mix of B2B and B2C driven by large Test menu Q1FY23 Q1FY24 Q1FY23 Q1FY24 Core Busines
Slide 19: Q1FY24 Consolidated Profit & Loss Statement
Q1FY24 Consolidated Profit & Loss Statement Profit & Loss Statement (Rs. Crs.) Q1FY24 Q1FY23 Y-o-Y Total Revenue from Operations 277.1 279.9 -1.0% Cost of operations 210.1 208.2 1.0% EBIDTA (before CSR & ESOP) 67.0 71.7 -6.6% EBIDTA (before CSR & ESOP) Margin 24.2% 25.6% CSR & ESOP 2.5 1.8 Reported
Slide 20: Metropolis 3.o: Opportunity
Metropolis 3.o : Opportunity
Slide 21: Addressable market expected to increase to ~Rs. 21K Cr by FY26
Addressable market is expected to increase to ~Rs. 21K Cr by FY26… Addressable market size FY23 FY26 CAGR ~INR 101K Cr ~INR 134K Cr 10% Radiology: ~INR 43K Cr Radiology: ~INR 58K Cr Radiology: 10% Indian diagnostics market Pathology: ~INR 76K Cr Pathology: 10% Pathology: ~INR 58K Cr ~INR 58K Cr ~INR
Slide 22: Metropolis to grow faster than the Industry
…Metropolis to grow faster than the Industry Strategy to Win Higher reliability of the Metropolis Brand with Specialized Doctor Network Large Network (including current expansion) to Increase the product suite for Premium help grow faster in Focus Cities and strengthen Wellness and create a sticky c
Slide 23: Customer Centric Front End Digital Infrastructure
Customer Centric Front End Digital Infrastructure Website orientation & development Revamped the Website for ease of customer queries & usage 01 Achieved 1 Mn plus website traffic Digital brand building 02 2.5x growth in brand reach and 4x growth engagement via Influencer campaigns WhatsApp campaign
Slide 24: Creating a Digital Transformation for business to grow
Creating a Digital Transformation for business to grow Enhanced Plans Benefits Productivity • A Fully Scaled Application Programming • Digital Leadership Rapid Scalability Interface (API) - Centric Tech Core • Full-fledged Customer Relationship • Faster go-to-market Management (CRM) stack for Servic
Slide 25: Metropolis - Certified Great Place to Work
Metropolis – Certified Great Place to Work Metropolis is the First Indian Diagnostic Organization for getting Great Place To Work certification. EMPLOYEE BRAND- Our Identity Attributes that Build Our Culture Trust, Openness, Innovation, Compassion & Growth Mindset Communicate Amplify with Talent Com
Slide 26: Metropolis ESG Journey
Metropolis ESG Journey Well identified ESG Focus Areas and assessments ESG Initiatives in FY 22-23 ESG Roadmap for FY 23-24 are created as per the materiality matrix based on Focus on Energy Conservation, Water and Waste Management. the GRI, SASB and SDG Frameworks. Full BSSR Stepped into our missio
Slide 27: CSR at Metropolis
CSR at Metropolis Too Shy to Ask (TSTA) MedEngage Preventive health Care Project DSEU*( Delhi Skills Outreach and Digital Program Programme Entrepreneurial University) • Metropolis Foundation, the CSR • The annual MedEngage Scholarship • Under the CSR intiiatives, • DSEU has collaborated with arm of
Slide 28: For further information, please contact
For further information, please contact: Company : Investor Relations Advisors : Metropolis Healthcare Ltd. Strategic Growth Advisors Pvt. Ltd. CIN – L73100MH2000PLC192798 CIN - U74140MH2010PTC204285 Mr. Rakesh Agarwal - CFO Mr. Shogun Jain / Mr. Sagar Shroff Email Id – rakesh.agarwal@metropolisindi
Metropolis Healthcare — Q1 FY2024 Earnings Presentation on 6ix